

Bereskin & Parr

Barristers and Solicitors/Patent and Trade Mark Agents
Practice Restricted to Intellectual Property Law

Micheline Gravelle B.Sc., M.Sc. (Immunology.)
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 09/442,143
Our Reference: 9579-14

November 2, 2001

By Facsimile**AFTER FINAL**

The Commissioner of Patent and Trademark
Washington, D.C. 20231
U.S.A.

Dear Sir:

Re: **RESPONSE**
United States Patent Application No. 09/442,143
Filed: November 15, 1999
Entitled: Methods of Modulating Immune Coagulation
Inventors: Gary Levy and David A. Clark
Examiner: P. Nolan
Art Unit: 1644

The present letter is filed in response to the office action dated September 24, 2001.
This response is being filed within two months from the date of the final action.

Please amend the application as follows

In the Specification:

Please replace the paragraphs at page 5, line 4 to line 6 with the following rewritten paragraphs:

—Figure 6 is the amino acid sequence of the mouse (SEQ.ID.NO.4) and human (SEQ.ID.NO.2) Fgl2 proteins, with the 5 glycosylation sites underlined;

Figure 7 shows the predicted secondary structure of the hFgl2 protein (SEQ.ID.NO.2);—